NDAORALTABLETPriority Review
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
ARIMIDEX (anastrozole) by AstraZeneca is estrogens. First approved in 2008.
Drug data last refreshed 10h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARIMIDEX (anastrozole) is a selective non-steroidal aromatase inhibitor that suppresses estrogen biosynthesis by blocking the aromatase enzyme in postmenopausal women. It is used to treat hormone receptor-positive breast cancer by significantly lowering serum estradiol concentrations without affecting adrenal corticosteroid or aldosterone production. The drug is administered orally as a tablet and represents a cornerstone endocrine therapy approach in oncology.
$4MPart D
LOE ApproachingDeclining
Product is in late-stage decline with minimal Part D utilization, signaling reduced commercial investment and smaller dedicated team sizes.
Mechanism of Action
estrogens. In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
Started Jan 2024
231 enrolled
Breast Cancer
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Started Feb 2023
152 enrolled
Breast Cancer
Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
Started Dec 2022
80 enrolled
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Started Jan 2021
14 enrolled
Refractory Endometrial AdenocarcinomaRefractory Endometrial CarcinomaRefractory Endometrial Clear Cell Adenocarcinoma+4 more
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Started Jan 2021
1,370 enrolled
ER-Positive HER2-Negative Breast Cancer
Worked on ARIMIDEX at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.